CRISPR Therapeutics AG (CRSP) Institutional Ownership & Insider Trading

520 institutions reported holding CRISPR Therapeutics AG shares in 13F filings for the quarter ended 2026-06-30, according to EquiReason's reading of their SEC filings. 33 insider trades on Form 4 since 2025-10-01.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

CRSPCRISPR Therapeutics AGFollow CRSP — free

Biotechnology · Healthcare

—

Price chart with a free account

Market cap: 4.8B
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 4 Nov, in 11 days

Institutions · all 13F filers

quarter to 30 Jun 2026 · filers in both quarters

520 institutions held 78.9% of the shares. Across filers that reported both quarters, shares held changed -1.4%.

Largest moves, shares (millions)

Institutional flow by quarter

net shares added or trimmed, millions · filers in both quarters

Quarter	Holders	Shares held, M	Change	Increased	New	Decreased	Closed
Jun 26	520	76	-1.4%	143	63	129	36
Mar 26	487	77	-0.9%	159	55	105	45
Dec 25	469	78	+2.4%	136	59	113	44
Sep 25	428	73	+0.8%	128	61	109	41
Jun 25	422	72	+12.2%	112	82	94	45
Mar 25	379	64	+0.1%	112	38	89	49
Dec 24	393	65	+7.8%	108	34	107	60
Sep 24	405	59	+0.0%	110	30	121	56

CRISPR Therapeutics AG — questions

Who owns CRISPR Therapeutics AG stock?: 520 institutions reported CRISPR Therapeutics AG shares in 13F filings for the quarter ended 2026-06-30. The largest: ARK Investment Management LLC (9.8%), BlackRock, Inc. (8.6%), Orbis Allan Gray Ltd (5.6%).
Are CRISPR Therapeutics AG insiders buying or selling?: 33 insider trades on Form 4 since 2025-10-01; the full list, with dates, people and plan status, is on this page.

Every figure on this page comes from CRISPR Therapeutics AG's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.